📖

APOE contributes to Alzheimer's disease by regulating both beta-amyloid deposition

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-hypotheses-apoe-contributes-alzheim

Related Entities

hypotheses-apoe-contributes-alzheimer's-disease-regulat

Metadata

slug	hypotheses-apoe-contributes-alzheimer's-disease-regulat
entity_type	hypothesis
kg_node_id	None

Linked Artifacts (766)

mentions🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%

related🧪APOE Isoform Expression Across Glial Subtypes90%

related🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%

mentions🧪APOE Isoform Conversion Therapy85%

mentions🧪APOE4-Selective Lipid Nanoemulsion Therapy85%

mentions🧫GWAS of plasma NfL in East Asian cohort80%

mentions🧫GWAS of composite biomarker score80%

mentions🧫GWAS of plasma pTau217 in East Asian cohort80%

mentions🧫Dairy intake and dementia risk in Malmö Diet and Cancer coho80%

mentions🧫GWAS of plasma pTau181 in East Asian cohort80%

mentions🧫RBG treatment in ApoE-/- atherosclerosis mouse model80%

mentions🧫GWAS of plasma GFAP in East Asian cohort80%

mentions🧫KEEPS Continuation: Long-term effects of menopausal hormone 80%

mentions🧫APOE4 association with TDP-43 pathology in AD80%

mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer80%

mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones80%

mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction80%

mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy80%

mentions🧪Competitive APOE4 Domain Stabilization Peptides80%

mentions🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#80%

mentions🧫Blood-Based Biomarker Panel for Early AD Detection80%

related🧪HSP90-Tau Disaggregation Complex Enhancement80%

related🧪VCP-Mediated Autophagy Enhancement80%

related🧪LRP1-Dependent Tau Uptake Disruption80%

related🧪Extracellular Vesicle Biogenesis Modulation80%

related🧪Synaptic Vesicle Tau Capture Inhibition80%

related🧪TREM2-mediated microglial tau clearance enhancement80%

related🧪Trans-Synaptic Adhesion Molecule Modulation80%

related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia80%

related🧪GFAP-Positive Reactive Astrocyte Subtype Delineation80%

related🧪Complement C1QA Spatial Gradient in Cortical Layers80%

related🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation80%

related🧪APOE Isoform Expression Across Glial Subtypes80%

related🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro80%

related🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli80%

related🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK80%

related🧪Prefrontal sensory gating circuit restoration via PV interne80%

related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna80%

related🧪Gamma entrainment therapy to restore hippocampal-cortical sy80%

see_also📖LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE80%

see_also📖LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy for 80%

see_also📖Alzheimer's Disease Biomarkers80%

see_also📖ASL Perfusion Biomarkers for Alzheimer's Disease80%

see_also📖Digital Biomarkers for Alzheimer's Disease80%

see_also📖Dried Blood Spot Biomarker Test for Alzheimer's Disease80%

see_also📖DTI Biomarkers for Alzheimer's Disease80%

see_also📖EEG Biomarkers for Alzheimer's Disease80%

see_also📖Eye-Tracking Digital Markers in Alzheimer's Disease80%

see_also📖Gait Biomarkers for Alzheimer's Disease80%

see_also📖GFAP in Alzheimer's Disease80%

see_also📖Inflammatory Biomarkers in Alzheimer's Disease80%

see_also📖Neurogranin - Alzheimer's Disease Biomarker80%

see_also📖NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease80%

see_also📖Ocular Fluid Biomarkers for Alzheimer's Disease80%

see_also📖Olfactory Biomarkers for Alzheimer's Disease80%

see_also📖Plasma Phospho-Tau Ratio Diagnostic Panel for Alzheimer'80%

see_also📖Salivary Biomarkers for Alzheimer's Disease80%

see_also📖Sleep Biomarkers for Alzheimer's Disease80%

see_also📖Speech and Cognitive Biomarkers for Alzheimer's Disease80%

see_also📖Synaptic Biomarkers for Alzheimer's Disease80%

see_also📖Tear Film Biomarkers in Alzheimer's Disease80%

see_also📖VILIP-1 and YKL-40 - Alzheimer's Disease Biomarkers80%

see_also📖Diffuse Amyloid Deposits in Alzheimer's Disease80%

see_also📖ACP-204 for Alzheimer's Disease Psychosis (NCT06159673)80%

see_also📖ASN90 Phase 2 Trial - Early Alzheimer's Disease (NCT05680%

see_also📖BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer80%

see_also📖BMS-986368 Phase 2 - Agitation in Alzheimer's Disease80%

see_also📖BMS-986446 Phase 2 Trial for Early Alzheimer's Disease80%

see_also📖Centella asiatica Phase 1 Trial for Alzheimer's Disease80%

see_also📖Escitalopram for Agitation in Alzheimer's Disease (NCT080%

see_also📖Fasudil for Early Alzheimer's Disease (FEAD) - NCT0636280%

see_also📖[F-18]Flornaptitril PET - Phase 3 for Alzheimer's Disea80%

see_also📖Foralumab Phase 2 Trial for Alzheimer's Disease80%

see_also📖GSK4527226 (AL101) for Early Alzheimer's Disease (NCT0680%

see_also📖Guanfacine NorAD - Phase 3 Trial for Alzheimer's Diseas80%

see_also📖IGC-AD1 for Agitation in Alzheimer's Disease (NCT05543680%

see_also📖ITI-1284 for Alzheimer's Disease Psychosis (NCT0654083380%

see_also📖KarXT (Xanomeline/Trospium) - Phase 3 for Alzheimer's D80%

see_also📖NCT03875638 - Levetiracetam for Alzheimer's Disease80%

see_also📖LHP588: P. gingivalis Targeting for Alzheimer's Disease80%

see_also📖MAR Polypill for Alzheimer's Disease (NCT06597058)80%

see_also📖Masupirdine for Alzheimer's Disease Agitation80%

see_also📖Masupirdine for Agitation in Alzheimer's Disease (NCT0580%

see_also📖MK-2214 for Early Alzheimer's Disease80%

see_also📖Nabilone for Agitation in Alzheimer's Disease (NCT0451680%

see_also📖NAB-IT: Nabilone for Agitation in Alzheimer's Disease80%

see_also📖TRAILBLAZER-ALZ 3 (NCT05026866) — Donanemab for Preclinical 80%

see_also📖GV1001 for Moderate to Severe Alzheimer's Disease (NCT080%

see_also📖Biogen Alzheimer's Disease Phase 2 Trial (NCT05399888)80%

see_also📖CBD (Cannabidiol) for Alzheimer's Disease Agitation - N80%

see_also📖GSK4527226 (AL101) for Early Alzheimer's Disease (NCT0680%

see_also📖KarXT for Alzheimer's Disease Cognitive Impairment - MI80%

see_also📖NRTIs for Alzheimer's Disease - Phase 1 (NCT07210528)80%

see_also📖DMB-I (Latrepirdine) Phase 3 (NCT07251023) — Alzheimer'80%

see_also📖NCT06582706: Nicotinic Acid for Alzheimer's Disease80%

see_also📖NRTIs for Alzheimer's Disease: Targeting Type-I Interfe80%

see_also📖ONO-2020 for Alzheimer's Disease (NCT06881836)80%

see_also📖NCT06803823 - ONO-2020 for Agitation in Alzheimer's Dis80%

see_also📖Ozanimod for Alzheimer's Disease (NCT06862960)80%

see_also📖Piromelatine 20 mg for Mild Dementia Due to Alzheimer's80%

see_also📖PLX5622 CSF1R Inhibitor Trial in Early Alzheimer's Dise80%

see_also📖Probiotics in Mild Alzheimer's Disease (NCT06181513)80%

see_also📖Recombinant Human Serum Albumin for Alzheimer's Disease80%

see_also📖Senicapoc Alzheimer's Disease Trial - NCT0480424180%

see_also📖SHR-1707 for Alzheimer's Disease (NCT06199037)80%

see_also📖Siponimod for Alzheimer's Disease (NCT06639282)80%

see_also📖SNIFF-Combo: Intranasal Insulin + Empagliflozin for Alzheime80%

see_also📖SToP-AD: Suvorexant for Alzheimer's Disease Prevention80%

see_also📖Alzheimer's Disease Mechanism Index80%

see_also📖CD33 Siglec Receptor Dysfunction Alzheimer's Disease Ca80%

see_also📖Cholinergic System Degeneration in Alzheimer's Disease80%

see_also📖EEG Microstates in Alzheimer's Disease80%

see_also📖Glymphatic System in Alzheimer's Disease80%

see_also📖Locus Coeruleus Degeneration in Alzheimer's Disease80%

see_also📖Metal Ion Homeostasis in Alzheimer's Disease80%

see_also📖Neuroinflammation in Alzheimer's Disease80%

see_also📖Sex-Specific Mechanisms in Alzheimer's Disease80%

see_also📖Sleep and Circadian Dysfunction in Alzheimer's Disease80%

see_also📖Tau Kinase-Phosphatase Balance in Alzheimer's Disease80%

see_also📖Tau Kinase Signaling Cascade in Alzheimer's Disease80%

see_also📖Ubiquitin-Proteasome System Dysfunction in Alzheimer's 80%

see_also📖EX039 Phase 2 (NCT05413655) — Oral Therapeutic for Alzheimer80%

see_also📖ExPlas — Exercise Plasma Transfusion for Alzheimer's Di80%

see_also📖Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's Dise80%

see_also📖LEAF Trial - THC+CBD for Alzheimer's Disease Agitation 80%

see_also📖Synaptic Therapy Alzheimer's Research Trial (START): A 80%

see_also📖The Alzheimer's Disease Tau Platform Clinical Trial (NC80%

see_also📖KarXT for Alzheimer's Disease Cognitive Impairment - MI80%

see_also📖Novartis Alzheimer's Disease Phase 2 Trial (NCT0709451680%

see_also📖X/T + X-EC + Lecanemab Phase 2 (NCT07212062) — Alzheimer80%

see_also📖Exciva Alzheimer's Disease Phase 2/3 Trial80%

see_also📖NCT07262645: Near-Infrared Light Therapy for Mild-Moderate A80%

see_also📖TRAP-AD: Transcranial Photobiomodulation for Alzheimer'80%

see_also📖VY7523 Phase 1/2 Alzheimer's Disease Trial80%

see_also📖APOE Lipid Metabolism Pathway in Alzheimer's Disease80%

see_also📖APOE4 and Alzheimer's Disease Risk80%

see_also📖Endolysosomal Pathway in Alzheimer's Disease80%

see_also📖Geniposide for Alzheimer's disease - immune biomarker t80%

see_also📖Mitochondrial Dysfunction in Alzheimer's Disease Pathwa80%

see_also📖Neuroinflammation Hypothesis in Alzheimer's Disease80%

see_also📖Neurovascular Dysfunction in Alzheimer's Disease: Integ80%

see_also📖NLRP3 Inflammasome Pathway in Alzheimer's Disease80%

see_also📖Sporadic Alzheimer's Disease Pathway80%

see_also📖Synaptic Loss in Alzheimer's Disease Pathway80%

see_also📖Vascular Dementia Mechanisms — Overlap with Alzheimer's80%

see_also📖Cannabidiol for Alzheimer's Disease Prevention (NCT058280%

see_also📖EI-1071 Immunomodulator for Alzheimer's Disease (NCT06780%

see_also📖A Phase 3, Randomised, Double-blinded, Placebo-controlled St80%

see_also📖Master Screening Study to Determine Individuals With Potenti80%

see_also📖Rotigotine and Rivastigmine Combination Therapy for Alzheime80%

see_also📖NCT07477431 - Levetiracetam for Persons at Risk for Alzheime80%

see_also📖TRAILRUNNER-ALZ 1: Remternetug for Early Alzheimer's Di80%

see_also📖Adipose-Derived Mesenchymal Stem Cell Therapy for Early Alzh80%

related🧪APOE4-Selective Lipid Nanoemulsion Therapy76%

mentions🔬Lipid metabolism dysregulation and membrane integrity in Alz75%

mentions🔬Analysis question not specified75%

see_also📖BEACoN Study - Biomarker Exploration in Aging, Cognition and75%

see_also📖nct0550878975%

see_also📖ALA-enriched Nutrition for APOE4 Carriers with MCI (NCT0739275%

see_also📖remternetug-anti-amyloid-alzheimers75%

see_also📖UPenn Observational Research Repository (NCT04715399)75%

see_also📖Endosomal-Lysosomal Pathway in Neurodegeneration75%

see_also📖Endosomal Sorting Defects in Neurodegeneration75%

see_also📖Neural Circuit Disruption in Neurodegeneration75%

see_also📖Senescent Cell Clearance in Neurodegeneration75%

related🧫GWAS of plasma NfL in East Asian cohort72%

related🧫GWAS of composite biomarker score72%

related🧫GWAS of plasma pTau217 in East Asian cohort72%

related🧫Dairy intake and dementia risk in Malmö Diet and Cancer coho72%

related🧫GWAS of plasma pTau181 in East Asian cohort72%

related🧫RBG treatment in ApoE-/- atherosclerosis mouse model72%

related🧫GWAS of plasma GFAP in East Asian cohort72%

related🧫KEEPS Continuation: Long-term effects of menopausal hormone 72%

related🧫APOE4 association with TDP-43 pathology in AD72%

related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia72%

related🧪GFAP-Positive Reactive Astrocyte Subtype Delineation72%

related🧪Complement C1QA Spatial Gradient in Cortical Layers72%

related🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation72%

related🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro72%

related🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli72%

related🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK72%

mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer70%

mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones70%

mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction70%

mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy70%

mentions🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides70%

mentions🧪Competitive APOE4 Domain Stabilization Peptides70%

mentions🧪APOE Isoform Expression Across Glial Subtypes70%

mentions🧫Real-world safety study of Lecanemab in Japanese AD patients70%

mentions🧫s:** - Biochemical binding assays measuring PROTAC selectivi70%

mentions🧫DDT/DDE exposure and cognitive function in Latina women70%

mentions🧫Biomechanical Impact Profiles and Chronic Traumatic Encephal70%

mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%

mentions🧫ApoE4 Function in Alzheimer's Disease70%

mentions🧫Brain Connectivity-Targeted tACS Trial in Early AD70%

mentions🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera70%

mentions🧫Genetic Risk Modifiers in DLB Phenotype70%

mentions🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras70%

mentions🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera70%

mentions🧫GLP-1 Agonist Responder Prediction Study — Precision Medicin70%

mentions🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise70%

mentions🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr70%

mentions🧫Neural Stem Cell Therapy for Alzheimer's Disease70%

mentions🧫Normal Aging to Alzheimer's Disease Transition Trigger 70%

mentions🧫Sex Differences in Alzheimer's Disease — mechanisms and70%

mentions🧫Sleep and Circadian Dysfunction as Driver of Neurodegenerati70%

mentions🧫Traumatic Brain Injury and Alzheimer's Disease Relation70%

mentions🧫Biomechanical Impact Profiles and Chronic Traumatic Encephal70%

mentions🧫Vascular Contribution to Alzheimer's Disease — Beyond A70%

mentions🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol70%

mentions🧫Viral Infections and Alzheimer's Disease — causal mecha70%

related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi70%

related🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau70%

related🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#70%

related🧫Blood-Based Biomarker Panel for Early AD Detection70%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%

related🧫Animal Model Comparison for Neurodegenerative Disease Therap70%

related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%

related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%

related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag70%

related🧫Neural Oscillation Dysfunction Validation in Parkinson'70%

related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%

related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%

related🧫Protein Aggregation Kinetic Validation Results70%

related🧫Purinergic Signaling Dysfunction Validation in Parkinson70%

related🧫Regulated Necrosis Validation Study in Parkinson's Dise70%

related🧫Stress Granule Dysfunction Validation in Parkinson's Di70%

related🧫Experiment Validation: In vitro ThT Assay70%

related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi70%

related🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau70%

related🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#70%

related🧫Blood-Based Biomarker Panel for Early AD Detection70%

related🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise70%

related🧫Sex Differences in Alzheimer's Disease — mechanisms and70%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%

related🧫Animal Model Comparison for Neurodegenerative Disease Therap70%

related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%

related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%

related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag70%

related🧫Neural Oscillation Dysfunction Validation in Parkinson'70%

related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%

related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%

related🧫Protein Aggregation Kinetic Validation Results70%

related🧫Purinergic Signaling Dysfunction Validation in Parkinson70%

related🧫Regulated Necrosis Validation Study in Parkinson's Dise70%

related🧫Stress Granule Dysfunction Validation in Parkinson's Di70%

related🧫Experiment Validation: In vitro ThT Assay70%

related🧪APOE Isoform Conversion Therapy70%

see_also📖APOE2 (Apolipoprotein E2)70%

see_also📖APOE3 (Apolipoprotein E3)70%

see_also📖APOE4 (Apolipoprotein E4)70%

see_also📖Extracellular Vesicle and Tunneling Nanotube-Mediated Spread70%

see_also📖Antibody Therapy in Neurodegeneration70%

see_also📖Axon Guidance Pathways in Neurodegeneration70%

see_also📖Cerebral Amyloid Angiopathy in Neurodegeneration70%

see_also📖Cerebral Amyloid Angiopathy Pathway in Neurodegeneration70%

see_also📖Convergent Pathways in Neurodegeneration70%

see_also📖COVID-19 Neurodegeneration Mechanism70%

see_also📖Down Syndrome Neurodegeneration Pathway70%

see_also📖Dystrophic Neurites in Neurodegeneration70%

see_also📖Galectin-3 Mechanism in Neurodegeneration70%

see_also📖gp130/IL-6 Family Cytokine Signaling in Neurodegeneration70%

see_also📖HMGB1 Signaling in Neurodegeneration70%

see_also📖IL-1 Signaling Pathway in Neurodegeneration70%

see_also📖Lipid Metabolism Dysregulation in Neurodegeneration70%

see_also📖Microglial Priming Pathway in Neurodegeneration70%

see_also📖Neurovascular Unit Dysfunction in Neurodegeneration70%

see_also📖Peripheral Immune-Brain Crosstalk in Neurodegeneration70%

see_also📖PPAR Signaling Pathway in Neurodegeneration70%

see_also📖Retinal Degeneration Pathway in Neurodegeneration70%

see_also📖RNA-Targeted Therapies in Neurodegeneration70%

see_also📖Sex Differences in Neurodegeneration70%

see_also📖Therapeutic Targets in Neurodegeneration70%

see_also📖Transdiagnostic Proteomic Changes in Neurodegeneration70%

related🔬Lipid metabolism dysregulation and membrane integrity in Alz67%

related🔬Analysis question not specified67%

see_also📖Cell-Free DNA Biomarkers in Neurodegeneration65%

see_also📖Exosomal Biomarkers in Neurodegeneration65%

see_also📖Exosomal miR-155 in Neurodegeneration65%

see_also📖IL-6 (Interleukin-6) in Neurodegeneration65%

see_also📖Liquid Biopsy in Neurodegeneration65%

see_also📖Metabolomic Biomarkers in Neurodegeneration65%

see_also📖Neuroimaging Biomarkers for Neurodegeneration65%

see_also📖Synaptic Biomarkers in Neurodegeneration65%

see_also📖Olfactory Mucosa, Blood and Urine for Identification of Earl65%

see_also📖Swedish BioFINDER 2 Study: Biomarkers and Neurodegeneration 65%

see_also📖Beta-Propeller Protein-Associated Neurodegeneration (BPAN)65%

see_also📖China Neurodegeneration Epidemiology65%

see_also📖DALY Methodology — Neurodegeneration65%

see_also📖Disease Progression & Staging in Neurodegeneration65%

see_also📖Economic Burden — Neurodegeneration65%

see_also📖European Neurodegeneration Epidemiology65%

see_also📖Familial vs Sporadic Neurodegeneration Comparison65%

see_also📖Global Neurodegeneration Epidemiology65%

see_also📖India Neurodegeneration Epidemiology65%

see_also📖Japan Neurodegeneration Epidemiology65%

see_also📖Manganese-Related Neurodegeneration (Manganism)65%

see_also📖mitochondrial-dysfunction-neurodegeneration-comparison65%

see_also📖Mitochondrial Diseases and Neurodegeneration Comparison Matr65%

see_also📖Mitochondrial Membrane Protein-Associated Neurodegeneration 65%

see_also📖Neurodegeneration with Brain Iron Accumulation (NBIA)65%

see_also📖Potential Impact Measures — Neurodegeneration65%

see_also📖Pantothenate Kinase-Associated Neurodegeneration (PKAN)65%

see_also📖PLA2G6-Associated Neurodegeneration (PLAN)65%

see_also📖Sleep Disorders in Neurodegeneration65%

see_also📖US Neurodegeneration Epidemiology65%

see_also📖acetylcholine-signaling-neurodegeneration65%

see_also📖Advanced Glycation End Products in Neurodegeneration65%

see_also📖Advanced In Vitro Models for Neurodegeneration — Organoids, 65%

see_also📖Amylin Signaling in Neurodegeneration65%

see_also📖Antisense Oligonucleotide (ASO) Therapy in Neurodegeneration65%

see_also📖Autosis Pathway in Neurodegeneration65%

see_also📖Basal Ganglia Circuit Dysfunction in Neurodegeneration65%

see_also📖becn1-autophagy-initiation-neurodegeneration-causal-chain65%

see_also📖CaMKII Signaling Pathway in Neurodegeneration65%

see_also📖Carbonic Anhydrase Modulator Therapy in Neurodegeneration65%

see_also📖Cholinergic System Dysfunction in Neurodegeneration65%

see_also📖Chrononutrition and Time-Restricted Eating in Neurodegenerat65%

see_also📖Neural Circuits in Neurodegeneration65%

see_also📖Cognitive Reserve and Resilience in Neurodegeneration65%

see_also📖Computational Disease Models for Neurodegeneration65%

see_also📖Copper Homeostasis in Neurodegeneration65%

see_also📖Diffusion MRI (DTI) in Neurodegeneration65%

see_also📖Digital Phenotyping in Neurodegeneration65%

see_also📖Endocannabinoid System in Neurodegeneration65%

see_also📖Endothelin Signaling Pathway in Neurodegeneration65%

see_also📖epigenetics-neurodegeneration65%

see_also📖ESCRT-III Inhibition by Alpha-Synuclein in Neurodegeneration65%

see_also📖FA2H-Associated Neurodegeneration Pathway65%

see_also📖Farnesoid X Receptor (FXR) Signaling in Neurodegeneration65%

see_also📖Gangliosides in Neurodegeneration65%

see_also📖GDF15/GDF11 Signaling in Neurodegeneration65%

see_also📖GDNF Signaling Pathway in Neurodegeneration65%

see_also📖Ghrelin Signaling Pathway in Neurodegeneration65%

see_also📖Glucocorticoid Signaling Pathway in Neurodegeneration65%

see_also📖Glycosylation in Neurodegeneration65%

see_also📖Hippocampal Neurogenesis in Neurodegeneration65%

see_also📖Histone Modification Pathways in Neurodegeneration65%

see_also📖Homocysteine Neurotoxicity and Neurodegeneration65%

see_also📖IGF-1 Signaling Pathway in Neurodegeneration65%

see_also📖Integrated Stress Response in Neurodegeneration65%

see_also📖interleukin-6-signaling-neurodegeneration65%

see_also📖Intrinsic Apoptosis Pathway in Neurodegeneration65%

see_also📖Ion Channel Dysfunction in Neurodegeneration: Cross-Disease 65%

see_also📖Kidney-Brain Neurodegeneration Axis65%

see_also📖Lipid Dysregulation in Neurodegeneration65%

see_also📖Lysosomal Calcium Dysregulation in Neurodegeneration65%

see_also📖Magnetic Resonance Spectroscopy in Neurodegeneration65%

see_also📖Metal Homeostasis Dysregulation in Neurodegeneration65%

see_also📖Metal Homeostasis in Neurodegeneration65%

see_also📖MicroRNA Dysfunction in Neurodegeneration65%

see_also📖Mineralocorticoid Receptor Signaling in Neurodegeneration65%

see_also📖Mitochondrial Dynamics Pathway in Neurodegeneration65%

see_also📖Mitochondrial Fusion in Neurodegeneration65%

see_also📖Molecular Chaperones in Neurodegeneration65%

see_also📖mTOR Signaling in Neurodegeneration65%

see_also📖mTOR Signaling Pathway in Neurodegeneration65%

see_also📖Neurexin/Neuroligin Synaptic Adhesion Modulator Therapy in N65%

see_also📖Neurofilament Light Chain (NfL) Mechanism in Neurodegenerati65%

see_also📖Neuronal Hyperexcitability in Neurodegeneration65%

see_also📖Neuropil Threads in Neurodegeneration65%

see_also📖Neurotensin Signaling in Neurodegeneration65%

see_also📖NF-kB Signaling Pathway in Neurodegeneration65%

see_also📖Nitric Oxide Signaling in Neurodegeneration65%

see_also📖Noradrenergic Signaling Pathway in Neurodegeneration65%

see_also📖Neuropeptide Y Signaling in Neurodegeneration65%

see_also📖NRF2 Signaling Pathway in Neurodegeneration65%

see_also📖Nuclear Pore Complex Dysfunction in Neurodegeneration65%

see_also📖Orexin Signaling in Neurodegeneration65%

see_also📖OSK Reprogramming and Yamanaka Factors in Neurodegeneration65%

see_also📖P-Body (Processing Body) Pathway in Neurodegeneration65%

see_also📖Paranodal Dysfunction in Neurodegeneration65%

see_also📖Paraptosis in Neurodegeneration65%

see_also📖Parthanatos in Neurodegeneration65%

see_also📖Pericyte Loss in Neurodegeneration65%

see_also📖PKR Pathway in Neurodegeneration65%

see_also📖Prion Diseases in Neurodegeneration65%

see_also📖Prion-Like Spread in Neurodegeneration65%

see_also📖Prion Protein Metabolism in Neurodegeneration65%

see_also📖Progesterone Signaling Pathway in Neurodegeneration65%

see_also📖Prognostic Biomarkers in Neurodegeneration65%

see_also📖Protein Aggregation Comparison in Neurodegeneration65%

see_also📖Protein Aggregation Seeds in Neurodegeneration65%

see_also📖Protein O-GlcNAcylation Pathway in Neurodegeneration65%

see_also📖Cortical Involvement and Neurodegeneration in Progressive Su65%

see_also📖Purinergic Signaling in Neurodegeneration65%

see_also📖Quantum Biology and Coherent Energy Transfer in Neurodegener65%

see_also📖R-Loop Stress in Neurodegeneration65%

see_also📖RAN Translation in Neurodegeneration65%

see_also📖Ribosome Dysfunction in Neurodegeneration65%

see_also📖RNA Splicing in Neurodegeneration65%

see_also📖Ribonuclease κ and Circular RNAs: A New Mechanism of Aging a65%

see_also📖S100 Protein Signaling Pathway in Neurodegeneration65%

see_also📖Serotonergic Dysfunction in Neurodegeneration65%

see_also📖Short Chain Fatty Acids in Neurodegeneration65%

see_also📖Sigma-1 Receptor Signaling in Neurodegeneration65%

see_also📖Sirtuin-Mitochondrial Biogenesis Axis in Neurodegeneration65%

see_also📖Sleep Dysfunction in Neurodegeneration65%

see_also📖SUMOylation in Neurodegeneration65%

see_also📖synaptic-vesicle-cycling-neurodegeneration65%

see_also📖Synthetic Lethality and PARP Inhibition in Neurodegeneration65%

see_also📖T-Cell Dysfunction in Neurodegeneration65%

see_also📖Tertiary Lymphoid Organs in Neurodegeneration65%

see_also📖ubiquitin-proteasome-dysfunction-neurodegeneration65%

see_also📖Ubiquitin-Proteasome System Dysfunction in Neurodegeneration65%

see_also📖Vagus Nerve Pathway in Neurodegeneration65%

see_also📖VEGF Signaling and Cerebral Angiogenesis in Neurodegeneratio65%

see_also📖vip-vasoactive-intestinal-peptide-signaling-neurodegeneratio65%

see_also📖WNK1-Bilirubin Signaling in Neuroinflammation and Neurodegen65%

see_also📖Wnt/β-Catenin Signaling Pathway in Neurodegeneration65%

related🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer63%

related🧪APOE4 Allosteric Rescue via Small Molecule Chaperones63%

related🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction63%

related🧪Targeted APOE4-to-APOE3 Base Editing Therapy63%

related🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides63%

related🧪Competitive APOE4 Domain Stabilization Peptides63%

related🧫Real-world safety study of Lecanemab in Japanese AD patients63%

related🧫s:** - Biochemical binding assays measuring PROTAC selectivi63%

related🧫DDT/DDE exposure and cognitive function in Latina women63%

related🧫Biomechanical Impact Profiles and Chronic Traumatic Encephal63%

related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri63%

related🧫Genetic Risk Modifiers in DLB Phenotype63%

related🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras63%

related🧫GLP-1 Agonist Responder Prediction Study — Precision Medicin63%

related🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise63%

related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr63%

related🧫Neural Stem Cell Therapy for Alzheimer's Disease63%

related🧫Sex Differences in Alzheimer's Disease — mechanisms and63%

related🧫Sleep and Circadian Dysfunction as Driver of Neurodegenerati63%

related🧫Biomechanical Impact Profiles and Chronic Traumatic Encephal63%

related🧪APOE Isoform Conversion Therapy63%

see_also📖al002-trem2-agonist-alzheimers60%

mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination60%

mentions🧪TREM2-Dependent Microglial Senescence Transition60%

mentions🧪TREM2-mediated microglial tau clearance enhancement60%

mentions🔬What are the mechanisms underlying mechanistic role of apoe 60%

related🧫s:** - Test whether HCN1 knockout specifically in EC layer I60%

related🧫Proposed experiment from debate on Synaptic pruning by micro60%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD60%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 60%

related🧫4R-Tau Targeting Therapies for PSP and CBS60%

related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti60%

related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?60%

related🧫Anti-Tau Immunotherapy Dosing Optimization60%

related🧫ApoE4 Function in Alzheimer's Disease60%

related🧫Experiment: Autoimmune Hypothesis Testing in AD60%

related🧫Autophagy Enhancement Drug Screening for Neurodegeneration60%

related🧫tACS Connectivity Trial in Early Alzheimer's60%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD60%

related🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 60%

related🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M60%

related🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera60%

related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera60%

related🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa60%

related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation60%

related🧫Gap Junction Dysfunction Validation in Parkinson's Dise60%

related🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas60%

related🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech60%

related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr60%

related🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis60%

related🧫Mixed Pathology Effects on Parkinson's Disease Progress60%

related🧫Neural Stem Cell Therapy for Alzheimer's Disease60%

related🧫Normal Aging to Alzheimer's Disease Transition Trigger 60%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 60%

related🧫Prion Strain Diversity and Selective Vulnerability60%

related🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease60%

related🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#60%

related🧫Sleep Disruption and Alzheimer's Disease — mechanism an60%

related🧫Traumatic Brain Injury and Alzheimer's Disease Relation60%

related🧫Tau ASO Therapy60%

related🧫Microglial TREM2 Agonist In Vivo Efficacy60%

related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia60%

related🧫Vascular Contribution to Alzheimer's Disease — Beyond A60%

related🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol60%

related🧫Viral Infections and Alzheimer's Disease — causal mecha60%

see_also📖A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month55%

see_also📖A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial55%

related🧪TREM2 Conformational Stabilizers for Synaptic Discrimination54%

related🧪TREM2-Dependent Microglial Senescence Transition54%

related🧪TREM2-mediated microglial tau clearance enhancement54%

related🔬What are the mechanisms underlying mechanistic role of apoe 54%

related🧫s:** - Test whether HCN1 knockout specifically in EC layer I54%

related🧫Proposed experiment from debate on Synaptic pruning by micro54%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD54%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 54%

related🧫4R-Tau Targeting Therapies for PSP and CBS54%

related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti54%

related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?54%

related🧫Anti-Tau Immunotherapy Dosing Optimization54%

related🧫ApoE4 Function in Alzheimer's Disease54%

related🧫Experiment: Autoimmune Hypothesis Testing in AD54%

related🧫Autophagy Enhancement Drug Screening for Neurodegeneration54%

related🧫tACS Connectivity Trial in Early Alzheimer's54%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD54%

related🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 54%

related🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M54%

related🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera54%

related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera54%

related🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa54%

related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation54%

related🧫Gap Junction Dysfunction Validation in Parkinson's Dise54%

related🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas54%

related🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech54%

related🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis54%

related🧫Mixed Pathology Effects on Parkinson's Disease Progress54%

related🧫Normal Aging to Alzheimer's Disease Transition Trigger 54%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 54%

related🧫Prion Strain Diversity and Selective Vulnerability54%

related🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease54%

related🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#54%

related🧫Sleep Disruption and Alzheimer's Disease — mechanism an54%

related🧫Traumatic Brain Injury and Alzheimer's Disease Relation54%

related🧫Tau ASO Therapy54%

related🧫Microglial TREM2 Agonist In Vivo Efficacy54%

related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia54%

related🧫Vascular Contribution to Alzheimer's Disease — Beyond A54%

related🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol54%

related🧫Viral Infections and Alzheimer's Disease — causal mecha54%

mentions🧪HSP90-Tau Disaggregation Complex Enhancement50%

mentions🧪VCP-Mediated Autophagy Enhancement50%

mentions🧪Prefrontal sensory gating circuit restoration via PV interne50%

mentions🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi50%

mentions🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau50%

mentions🧫Multi-omics analysis of myricanol effects on gene expression50%

mentions🧪Membrane Cholesterol Gradient Modulators50%

mentions🧪Circadian-Synchronized LRP1 Pathway Activation50%

mentions🧪Synthetic Biology BBB Endothelial Cell Reprogramming50%

mentions🧫Microglial TREM2 Agonist In Vivo Efficacy50%

mentions🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim50%

mentions🧫TREM2 Function in Alzheimer's Disease — From Risk Varia50%

mentions🧪Netrin-1 Gradient Restoration50%

mentions🧪Purinergic Signaling Polarization Control50%

mentions🧪Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration50%

mentions🧪Selective HDAC3 Inhibition with Cognitive Enhancement50%

mentions🧪CX43 hemichannel engineering enables size-selective mitochon50%

mentions🧪Multi-Modal Stress Response Harmonization50%

mentions🧪Complement C1q Mimetic Decoy Therapy50%

mentions🧪CYP46A1 Overexpression Gene Therapy50%

mentions🧪Metabolic Circuit Breaker via Lipid Droplet Modulation50%

mentions🧪Senescent Microglia Resolution via Maresins-Senolytics Combi50%

mentions🧪Palmitoylation-Targeted BACE1 Trafficking Disruptors50%

mentions🧪Microglial Efferocytosis Enhancement via GPR32 Superagonists50%

mentions🧪Nutrient-Sensing Epigenetic Circuit Reactivation50%

mentions🧪LRP1-Dependent Tau Uptake Disruption50%

mentions🧪SIRT6-NAD+ Axis Enhancement Therapy50%

mentions🧪Extracellular Vesicle Biogenesis Modulation50%

mentions🧪Circadian Rhythm Entrainment of Reactive Astrocytes50%

mentions🧪SASP-Mediated Complement Cascade Amplification50%

mentions🧪Complement C1q Subtype Switching50%

mentions🧪Microglial Purinergic Reprogramming50%

mentions🧪Autophagosome Maturation Checkpoint Control50%

mentions🧪Chaperone-Mediated APOE4 Refolding Enhancement50%

mentions🧪Sphingolipid Metabolism Reprogramming50%

mentions🧪Synaptic Vesicle Tau Capture Inhibition50%

mentions🧪Pericyte Contractility Reset via Selective PDGFR-β Agonism50%

mentions🧪Optogenetic Microglial Deactivation via Engineered Inhibitor50%

mentions🧪Lipid Droplet Dynamics as Phenotype Switches50%

mentions🧪Glycine-Rich Domain Competitive Inhibition50%

mentions🧪SASP-Driven Aquaporin-4 Dysregulation50%

mentions🧪Matrix Stiffness Normalization via Targeted Lysyl Oxidase In50%

mentions🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna50%

mentions🧪KDM6A-Mediated H3K27me3 Rejuvenation50%

mentions🧪Astrocyte-Mediated Neuronal Epigenetic Rescue50%

mentions🧪Stress Granule Phase Separation Modulators50%

mentions🧪Pharmacological Enhancement of APOE4 Glycosylation50%

mentions🧪Circadian Glymphatic Entrainment via Targeted Orexin Recepto50%

mentions🧪Temporal TET2-Mediated Hydroxymethylation Cycling50%

mentions🧪Chromatin Accessibility Restoration via BRD4 Modulation50%

mentions🧪Fractalkine Axis Amplification via CX3CR1 Positive Allosteri50%

mentions🧪Senescence-Associated Myelin Lipid Remodeling50%

mentions🧪Gamma entrainment therapy to restore hippocampal-cortical sy50%

mentions🧪Glial Glycocalyx Remodeling Therapy50%

mentions🧪Reelin-Mediated Cytoskeletal Stabilization Protocol50%

mentions🧪TET2-Mediated Demethylation Rejuvenation Therapy50%

mentions🧪Selective Acid Sphingomyelinase Modulation Therapy50%

mentions🧪Circadian Glymphatic Rescue Therapy (Melatonin-focused)50%

mentions🧪Phase-Separated Organelle Targeting50%

mentions🧪Cross-Seeding Prevention Strategy50%

mentions🧪Microbiome-Derived Tryptophan Metabolite Neuroprotection50%

mentions🧪FOXO3-Longevity Pathway Epigenetic Reprogramming50%

mentions🧪Trans-Synaptic Adhesion Molecule Modulation50%

related🔬What are the mechanisms underlying selective vulnerability o50%

related🔬What are the mechanisms underlying 4r-tau strain-specific sp50%

related🔬What are the mechanisms underlying tdp-43 phase separation t50%

related🔬What are the mechanisms underlying astrocyte reactivity subt50%

related🔬What are the mechanisms underlying blood-brain barrier trans50%

related🔬What are the mechanisms underlying microglia-astrocyte cross50%

related🔬What are the mechanisms underlying apoe4 structural biology 50%

related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%

related🔬What are the mechanisms underlying digital biomarkers and ai50%

related🔬What are the mechanisms underlying senolytic therapy for age50%

related🔬What are the mechanisms underlying neuroinflammation resolut50%

related🔬What are the mechanisms underlying what are the mechanisms b50%

related🔬Investigate how lipid raft composition (cholesterol metaboli50%

related🔬What are the mechanisms underlying sleep disruption as cause50%

related🔬What are the mechanisms underlying rna binding protein dysre50%

related🔬What are the mechanisms underlying synaptic pruning by micro50%

related🔬What are the mechanisms underlying mitochondrial transfer be50%

related🔬What are the mechanisms underlying epigenetic clocks and bio50%

related🔬What are the mechanisms underlying perivascular spaces and g50%

related🔬Analyze circuit-level changes in neurodegeneration using All50%

related🔬Epigenetic reprogramming in aging neurons50%

related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%

related🔬Investigate prion-like spreading of tau pathology through co50%

related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%

related🔬The disease-associated microglia (DAM) phenotype involves TR50%

related🔬What are the mechanisms underlying selective vulnerability o50%

related🔬What are the mechanisms underlying 4r-tau strain-specific sp50%

related🔬What are the mechanisms underlying tdp-43 phase separation t50%

related🔬What are the mechanisms underlying astrocyte reactivity subt50%

related🔬What are the mechanisms underlying blood-brain barrier trans50%

related🔬What are the mechanisms underlying microglia-astrocyte cross50%

related🔬What are the mechanisms underlying apoe4 structural biology 50%

related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%

related🔬What are the mechanisms underlying digital biomarkers and ai50%

related🔬What are the mechanisms underlying senolytic therapy for age50%

related🔬What are the mechanisms underlying neuroinflammation resolut50%

related🔬What are the mechanisms underlying what are the mechanisms b50%

related🔬Investigate how lipid raft composition (cholesterol metaboli50%

related🔬What are the mechanisms underlying sleep disruption as cause50%

related🔬What are the mechanisms underlying rna binding protein dysre50%

related🔬What are the mechanisms underlying synaptic pruning by micro50%

related🔬What are the mechanisms underlying mitochondrial transfer be50%

related🔬What are the mechanisms underlying epigenetic clocks and bio50%

related🔬What are the mechanisms underlying perivascular spaces and g50%

related🔬Analyze circuit-level changes in neurodegeneration using All50%

related🔬The disease-associated microglia (DAM) phenotype involves TR50%

related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%

related🔬What gene expression changes in the aging mouse brain predic50%

related🔬Epigenetic reprogramming in aging neurons50%

related🔬Comprehensive analysis of immune cell subtypes in neurodegen50%

related🔬What cell types are most vulnerable in Alzheimers Disease ba50%

related🔬What cell types are most vulnerable in Alzheimer's Dise50%

related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%

related🔬Investigate prion-like spreading of tau pathology through co50%

related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%

related🔬What are the most promising therapeutic strategies for targe50%

related🔬How to break the GBA-alpha-synuclein bidirectional loop for 50%

related🔬Can gut-brain axis modulation prevent or slow Alzheimer'50%

related🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph50%

related🔬Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% br50%

related🔬APOE4 differs from APOE3 by C112R causing domain interaction50%

see_also📖CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD50%

see_also📖DBS Nucleus Basalis Trial (NCT07218081): Deep Brain Stimulat50%

see_also📖Donanemab TRAILBLAZER-ALZ 2 Trial50%

see_also📖MK-1167 Phase 2 AD Trial (MK-1167-008)50%

see_also📖A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, M50%

see_also📖Trontinemab (RO7126209) Phase 3 Trial — TRONTIER 2 (NCT0717050%

see_also📖UB-311 Alzheimer's Vaccination Trial50%

see_also📖Neuroimaging for Parkinsonian Syndromes (NCT03872102)45%

see_also📖Gene-Mechanism-Therapy Causal Chains45%

see_also📖TREM2 Gene-Mechanism-Therapy Chain — From Genetic Risk to Th45%

mentions🧫CRISPR Gene Correction Approaches for CBS/PSP44%

mentions🧫Anti-Tau Immunotherapy Dosing Optimization44%

mentions🧫Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo44%

mentions🧫Tau Propagation Causality Test — Does Tau Spread Drive Neuro44%

mentions🔬What cell types are most vulnerable in Alzheimer's Dise40%

mentions🔬What are the most promising therapeutic strategies for targe40%

mentions🔬Can gut-brain axis modulation prevent or slow Alzheimer'40%

mentions🔬What cell types are most vulnerable in Alzheimers Disease ba40%

mentions🔬How to break the GBA-alpha-synuclein bidirectional loop for 40%

mentions🔬Investigate how lipid raft composition (cholesterol metaboli40%

mentions🔬Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% br40%

mentions🔬APOE4 differs from APOE3 by C112R causing domain interaction40%

mentions🔬The disease-associated microglia (DAM) phenotype involves TR40%

mentions🔬What are the mechanisms underlying what are the mechanisms b40%

mentions🔬The disease-associated microglia (DAM) phenotype involves TR40%

mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%

mentions🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph40%

mentions🔬What gene expression changes in the aging mouse brain predic40%

mentions🔬Comprehensive analysis of immune cell subtypes in neurodegen40%

related🧪Netrin-1 Gradient Restoration40%

related🧪Purinergic Signaling Polarization Control40%

related🧪Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration40%

related🧪Selective HDAC3 Inhibition with Cognitive Enhancement40%

related🧪HSP90-Tau Disaggregation Complex Enhancement40%

related🧪CX43 hemichannel engineering enables size-selective mitochon40%

related🧪VCP-Mediated Autophagy Enhancement40%

related🧪Multi-Modal Stress Response Harmonization40%

related🧪Complement C1q Mimetic Decoy Therapy40%

related🧪CYP46A1 Overexpression Gene Therapy40%

related🧪Metabolic Circuit Breaker via Lipid Droplet Modulation40%

related🧪Senescent Microglia Resolution via Maresins-Senolytics Combi40%

related🧪Palmitoylation-Targeted BACE1 Trafficking Disruptors40%

related🧪Microglial Efferocytosis Enhancement via GPR32 Superagonists40%

related🧪Nutrient-Sensing Epigenetic Circuit Reactivation40%

related🧪LRP1-Dependent Tau Uptake Disruption40%

related🧪SIRT6-NAD+ Axis Enhancement Therapy40%

related🧪Extracellular Vesicle Biogenesis Modulation40%

related🧪Circadian Rhythm Entrainment of Reactive Astrocytes40%

related🧪SASP-Mediated Complement Cascade Amplification40%

related🧪Complement C1q Subtype Switching40%

related🧪Microglial Purinergic Reprogramming40%

related🧪Autophagosome Maturation Checkpoint Control40%

related🧪Prefrontal sensory gating circuit restoration via PV interne40%

related🧪Chaperone-Mediated APOE4 Refolding Enhancement40%

related🧪Sphingolipid Metabolism Reprogramming40%

related🧪Synaptic Vesicle Tau Capture Inhibition40%

related🧪Pericyte Contractility Reset via Selective PDGFR-β Agonism40%

related🧪Optogenetic Microglial Deactivation via Engineered Inhibitor40%

related🧪Lipid Droplet Dynamics as Phenotype Switches40%

related🧪Circadian-Synchronized LRP1 Pathway Activation40%

related🧪Glycine-Rich Domain Competitive Inhibition40%

related🧪SASP-Driven Aquaporin-4 Dysregulation40%

related🧪Matrix Stiffness Normalization via Targeted Lysyl Oxidase In40%

related🧪Synthetic Biology BBB Endothelial Cell Reprogramming40%

related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna40%

related🧪KDM6A-Mediated H3K27me3 Rejuvenation40%

related🧪Astrocyte-Mediated Neuronal Epigenetic Rescue40%

related🧪Stress Granule Phase Separation Modulators40%

related🧪Pharmacological Enhancement of APOE4 Glycosylation40%

related🧪Membrane Cholesterol Gradient Modulators40%

related🧪Circadian Glymphatic Entrainment via Targeted Orexin Recepto40%

related🧪Temporal TET2-Mediated Hydroxymethylation Cycling40%

related🧪Chromatin Accessibility Restoration via BRD4 Modulation40%

related🧪Fractalkine Axis Amplification via CX3CR1 Positive Allosteri40%

related🧪Senescence-Associated Myelin Lipid Remodeling40%

related🧪Gamma entrainment therapy to restore hippocampal-cortical sy40%

related🧪Glial Glycocalyx Remodeling Therapy40%

related🧪Reelin-Mediated Cytoskeletal Stabilization Protocol40%

related🧪TET2-Mediated Demethylation Rejuvenation Therapy40%

related🧪Selective Acid Sphingomyelinase Modulation Therapy40%

related🧪Circadian Glymphatic Rescue Therapy (Melatonin-focused)40%

related🧪Phase-Separated Organelle Targeting40%

related🧪Cross-Seeding Prevention Strategy40%

related🧪Microbiome-Derived Tryptophan Metabolite Neuroprotection40%

related🧪FOXO3-Longevity Pathway Epigenetic Reprogramming40%

related🧪Trans-Synaptic Adhesion Molecule Modulation40%

related🔬Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% br40%

related🔬Senescent cell clearance as neurodegeneration therapy40%

related🔬Tau propagation mechanisms and therapeutic interception poin40%

related🔬PSP and CBD both involve 4R-tau but produce distinct neuropa40%

mentions🔬What are the mechanisms underlying selective vulnerability o35%

mentions🔬What are the mechanisms underlying 4r-tau strain-specific sp35%

mentions🔬What are the mechanisms underlying tdp-43 phase separation t35%

mentions🔬What are the mechanisms underlying astrocyte reactivity subt35%

mentions🔬What are the mechanisms underlying blood-brain barrier trans35%

mentions🔬What are the mechanisms underlying microglia-astrocyte cross35%

mentions🔬What are the mechanisms underlying apoe4 structural biology 35%

mentions🔬What are the mechanisms underlying autophagy-lysosome pathwa35%

mentions🔬What are the mechanisms underlying digital biomarkers and ai35%

mentions🔬What are the mechanisms underlying senolytic therapy for age35%

mentions🔬What are the mechanisms underlying neuroinflammation resolut35%

mentions🔬What are the mechanisms underlying sleep disruption as cause35%

mentions🔬What are the mechanisms underlying rna binding protein dysre35%

mentions🔬What are the mechanisms underlying synaptic pruning by micro35%

mentions🔬What are the mechanisms underlying mitochondrial transfer be35%

mentions🔬What are the mechanisms underlying epigenetic clocks and bio35%

mentions🔬What are the mechanisms underlying perivascular spaces and g35%

mentions🔬Analyze circuit-level changes in neurodegeneration using All35%

mentions🔬Epigenetic reprogramming in aging neurons35%

mentions🔬Investigate prion-like spreading of tau pathology through co35%